By: Erica Larson In 2014 the U.S. Food and Drug Administration approved two bisphosphonate drugs—clodronate and tiludronate—for controlling clinical signs associated with podotrochlosis (more commonly known as navicular syndrome) in horses ages 4 and older. Since then, some veterinarians have started using these products off-label to treat other equine bone issues, such as bucked shins